Ikena Oncology, Inc. has announced an update on its merger agreement involving Insight Merger Sub I, Insight Merger Sub II, and Inmagene Biopharmaceuticals. According to the updated terms, Insight Merger Sub I will merge with and into Inmagene, resulting in Inmagene becoming a direct, wholly owned subsidiary of Ikena. Following this, Inmagene will merge with Insight Merger Sub II, which will then become a direct, wholly owned subsidiary of Ikena. Additionally, Ikena's board of directors has approved a special dividend of one contingent value right $(CVR)$ for each outstanding share of Ikena common stock for stockholders of record as of July 24, 2025, entitling them to potential payments based on future proceeds received by Ikena. This update was disclosed by Ikena Oncology, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.